Latest Breaking News On - Chris savile - Page 3 : comparemela.com

WILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTS

Investment further validates Willow s technology for the development and sustainable manufacture of natural ingredients Additional capital will accelerate commercialization of Willow s pipeline.

Canada
Toronto
Ontario
Canadian
Chris-savile
Toronto-stock-exchange
Willow-biosciences-inc
Common-share
Each-warrant
Common-shares
Willow-biosciences
Additional-investment

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Canada
Canadian
Chris-savile
Willow-biosciences-inc
Willow-biosciences
Active-pharmaceutical-ingredient

Willow Bioscience announces unique collaboration with Enterin Inc

Willow Bioscience announces unique collaboration with Enterin Inc
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Chris-savile
Willow-bioscience
Steve-darling
Proactive-enterin

WILLOW ANNOUNCES COLLABORATION WITH ENTERIN TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

/PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial.

Canada
Canadian
Chris-savile
Enterin-inc
Willow-biosciences-inc
Willow-biosciences
Willow-biosciences-inc

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Estimated FY 2023 revenues in excess of $1.3 million is a record year for the Company Anticipate closing at least three new partnership development agreements including one for our corticosteroid.

Canada
Canadian
Chris-savile
Willow-biosciences-inc
Willow-biosciences
San-francisco-bay
Cautionary-statements
Markets